HALO logo
halo search icon
Innoviva, Inc.

US$22.20

Price Change Indicator
-0.04 (-0.18%)
Innoviva, Inc.
INVA · NAS

Innoviva, Inc.

Start Trading INVA for Free

US$22.20

Price Arrow-0.04 (-0.18%)
21/05/2026 04:00:00 PM
All-CompaniesAll-ConsensusConsensus CheapFakey Shakey - LongFakey Shakey - Long (Realtime)HALO AllHALO Earnings MomentumHALO Momentum+3
Consensus Score
Lock Icon/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

Innoviva, Inc. Overview

INVA Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

HALO Model

Mqv

Very Weak

Garp

Very Weak

Mqv Small

Neutral

Valuation

Value

Lock Icon

Consensus

Lock Icon

Momentum

Price

Weak

Earnings

Very Strong

Growth

Earnings

Weak

Dividends

Very Weak

Quality

Capital Efficiency

Very Weak

Balance Sheet

Very Weak

About INVA

icon
icon

Telephone

1.650.238.9600

icon

Address

Suite 400, 1350 Old Bayshore Highway, Burlingame, CA 94010

Description

Innoviva, Inc. engages in the development, commercialization, and financial management of biopharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate, and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.

INVA Price Chart

Key Stats

Market Cap

US$1.64B

PE

6.10

EV/EBITDA

6.8

Dividends Overview

DIV Yield

0%

Franking

0%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 16.52 - 25.15

Trade Value (12mth)

US$4,204,070.00

1 week

1.23%

1 month

-5.36%

YTD

11.93%

1 year

18.17%

All time high

34.61

Key Fundamentals

EPS 3 yr Growth

31.00%

EBITDA Margin

48.00%

Operating Cashflow

$197m

Free Cash Flow Return

16.50%

ROIC

22.70%

Interest Coverage

12.20

Quick Ratio

13.90

Other Data

Shares Outstanding (Fully Diluted)

85m

HALO Sector

Healthcare

Next Company Report Date

03-Mar-27

Next Ex Dividend Date

N/A

Next Dividend Pay Date

N/A

Reporting Currency

USD

Short Sell (% of issue)

0.00

INVA Announcements

Latest Announcements

DateAnnouncements
19 May 26
19 May 26
07 May 26
07 May 26
07 May 26

INVA Fundamentals

Per Share Records

Historical data

Forecast data

USD2021202220232024202320242025202620272028
Per Share, Growth & Valuations
EPS (Basic)
 $locklocklocklock2.750.374.02locklocklock
EPS (Fully Diluted)
 $locklocklocklock2.20.363.3locklocklock
Growth
 %locklocklocklock-10.6-86.4979locklocklock
PE
 Xlocklocklocklock7.347.96.1locklocklock
EV/EBITDA
 Xlocklocklocklock116.46.8locklocklock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

0%

Franking Level

0%

DPSg

N/A

Quality Yield

lock

Falling Divs over next 2

lock

Want to learn more?Frequently asked questions.
What is the current share price of Innoviva, Inc. (INVA:NAS)?
Halo FAQ
The current share price of Innoviva, Inc. (INVA:NAS) is USD$22.20.
What is the 52-week high share price for Innoviva, Inc. (INVA:NAS)?
Halo FAQ
The 52-week high share price for Innoviva, Inc. (INVA:NAS) is USD$25.15.
What is the 52-week low share price for Innoviva, Inc. (INVA:NAS)?
Halo FAQ
The 52-week low share price for Innoviva, Inc. (INVA:NAS) is USD$16.52.
What is the dividend yield for Innoviva, Inc. (INVA:NAS)?
Halo FAQ
Innoviva, Inc. (INVA:NAS) does not pay a dividend.
What was Innoviva, Inc. (INVA:NAS) last dividend payment?
Halo FAQ
The last dividend payment of Innoviva, Inc. (INVA:NAS) is USD$0.25.
What is the franking level for Innoviva, Inc. (INVA:NAS)?
Halo FAQ
Innoviva, Inc. (INVA:NAS) has a franking level of 0.00%.
In which sector is Innoviva, Inc. (INVA:NAS) classified?
Halo FAQ
Innoviva, Inc. (INVA:NAS) is classified in the Healthcare.
What is the price-to-earnings (P/E) ratio for Innoviva, Inc. (INVA:NAS)?
Halo FAQ
The current P/E ratio for Innoviva, Inc. (INVA:NAS) is 6.10.

See beyond the curve.

One solution for research, investing and portfolio management.
Start FREE Trial